Inamul Hasan Madar | Medicine | Outstanding Scientist Award

Published on by Academic Excellence

Prof. Dr. Inamul Hasan Madar | Medicine | Outstanding Scientist Award

Prof. Dr. Inamul Hasan Madar | Medicine | Yenepoya Universtiy |India

Dr. Inamul Hasan Madar is a distinguished researcher and educator in the field of biochemistry with a specialization in oncology proteogenomics. He earned his PhD from Korea University, a globally ranked institution, and has since developed extensive expertise in cancer genomics, multiomics integration, and bioinformatics. With a strong commitment to advancing medical research, Dr. Madar has served as an adjunct faculty at Saveetha Medical College (SIMATS), where he has mentored PhD, MD, MBBS, and MSc students in cutting-edge biomedical sciences. His international research experience includes appointments at Korea University and Hanyang University in South Korea, where he contributed to high-impact oncology projects. As Director and Lead of Canary Oncoceutics India, he has bridged the gap between research and industry by leading innovative onco-therapeutic initiatives. Widely published in top-tier journals, Dr. Madar has also served as a reviewer for international journals and as a member of prestigious scientific societies worldwide.

Author profile

Orcid

Education

Dr. Madar’s academic journey reflects a deep pursuit of excellence in biomedical sciences. He earned his PhD in Biochemistry, specializing in Onco-Proteogenomics, from Korea University, Seoul, ranked among the top global universities. His doctoral work focused on proteogenomic profiling and cancer biomarker discovery, positioning him at the forefront of precision oncology. Before this, he pursued advanced training in bioinformatics, molecular biology, and proteomics, equipping him with multidisciplinary skills to tackle complex biomedical challenges. His postgraduate education emphasized molecular diagnostics and computational approaches, while his undergraduate studies laid the foundation in biochemistry and clinical applications. Dr. Madar has also completed specialized training programs in next-generation sequencing (NGS), computational modeling, molecular docking, and drug discovery pipelines. Furthermore, he has been actively engaged in faculty development programs, including pedagogy training for undergraduate teaching in life sciences and biotechnology. This comprehensive educational background underscores his ability to combine research innovation with academic excellence.

Experience

Dr. Madar’s professional experience spans academia, research, and industry. He currently serves as Adjunct Faculty at Saveetha Medical College, SIMATS, where he mentors MBBS, MD, MSc, MPhil, and PhD students in research methodologies, cancer biology, and bioinformatics. He is also Director and Lead (Marketing) at Canary Oncoceutics India, overseeing translational oncology research and innovation in oncoceutical product development. Internationally, he worked as a Visiting Scientist at Korea University, specializing in proteogenomics, and as a Researcher at Hanyang University, Seoul, in bioengineering. In India, his previous roles include Scientist & Course Coordinator at Biocuration, where he designed genomics and drug development modules, and Junior Scientist at iPro Technologies. He has also contributed as a guest lecturer at Bharathidasan University, training future biochemists. His expertise extends to designing computational pipelines, analyzing multiomics datasets, and leading cross-disciplinary projects that bridge laboratory science and clinical application, particularly in cancer therapeutics and biomarker discovery.

Awards and Honors

Dr. Inamul Hasan Madar has received widespread recognition for his contributions to biomedical research and education. His publications in high-impact journals such as Nature Cancer, Oncotarget, Briefings in Bioinformatics, and Molecular Cancer have positioned him among leading voices in proteogenomics and cancer research. He has served as a peer reviewer for several prestigious journals, including Nature’s Scientific Reports, Frontiers in Oncology, BMC Medical Genomics, and Journal of Translational Medicine. He has been actively involved in international professional societies, including the American Association of Cancer Research (AACR), American Society for Biochemistry and Molecular Biology (ASBMB), International Society of Computational Biology (ISCB), and South African and Korean Mass Spectrometry Societies. His leadership roles include serving as Vice President of ISCB-RSG India, demonstrating his dedication to strengthening scientific networks. He has also mentored numerous graduate and medical students, guiding them to publish impactful research, file patents, and develop translational medical applications.

Research Focus

Dr. Madar’s research focus lies at the intersection of cancer genomics, proteogenomics, and computational biology. He specializes in integrating multiomics datasets to identify novel biomarkers and therapeutic targets for treatment-resistant cancers, particularly cervical, prostate, and oral squamous cell carcinoma. His expertise in next-generation sequencing (RNA-Seq, Exome-Seq) and bioinformatics has enabled him to develop innovative pipelines for cancer biomarker discovery, molecular subtyping, and clinical variant interpretation. Beyond oncology, he has contributed to research in neurobiology, metabolic disorders, cardiovascular protection, and bioactive peptides against diabetes and obesity. His translational approach emphasizes the “bench-to-bedside” concept, applying computational models and molecular profiling to guide precision medicine strategies. Dr. Madar has also explored theranostic targets, signaling networks, and novel oncoceutical formulations. His interdisciplinary collaborations with international research groups have advanced drug design, CAR-T therapy applications, and personalized treatment strategies, positioning him as a pioneer in cancer research and translational medicine.

Publications

  • Correction to: Proteogenomic characterization of molecular and cellular targets for treatment-resistant cervical cancers.

  • Molecular analysis of HPV16 and HPV18 oncogenes in oral squamous cell carcinoma.

  • Proteogenomic characterization of treatment-resistant subtypes in cervical cancers.

  • Theranostic Target NSUN2 uncovered with systematic assembly of 805 datasets.

  • Unravelling the phosphoregulatory network of PKC-delta (PKC-δ).

  • BDNF-TrkB signalling: A neurotrophic pathway to cardiovascular protection.

  • Physiological activities of bioactive peptides against diabetes and obesity.

  • SGLT2 inhibitors as dual therapeutic targets for cardiovascular and renal health.

  • Biobased nanomaterials and rhizobacteria for sustainable plant growth.

  • CAR-T therapy in oral squamous cell carcinoma: Current innovations and future prospects.

Conclusion

Dr. Inamul Hasan Madar exemplifies excellence in translational medicine, combining cutting-edge cancer research with dedicated academic mentorship. His impactful publications, international collaborations, and leadership in oncology research position him as a transformative figure in biomedical sciences. Through his expertise in proteogenomics and bioinformatics, he continues to advance precision medicine while inspiring the next generation of medical researchers.

Syed Aasim Syed Nasir | Medicine | Excellence in Research

Published on by Academic Excellence

Mr. Syed Aasim Syed Nasir | Medicine | Excellence in Research

Mr. Syed Aasim Syed Nasir | Medicine | Tbilisi State Medical University | Georgia

Syed Aasim Syed Nasir is a dedicated fourth-year medical student at Tbilisi State Medical University, Georgia, committed to advancing medical research and clinical practice. His academic journey is complemented by extensive research contributions in cardiology, oncology, infectious diseases, and orthopedic surgery. With a growing publication record in reputed journals and conferences, he demonstrates strong skills in investigation, methodology, and medical writing. He has actively presented case reports, systematic reviews, and clinical studies at international platforms, earning recognition for his innovative insights. Beyond research, Syed Aasim is involved in leadership roles within medical organizations, fostering academic collaboration among peers worldwide. His internships and observerships in Dubai and Nigeria further enriched his exposure to diverse healthcare systems. Fluent in multiple languages and active in global medical societies, he exemplifies a well-rounded future physician-researcher with aspirations to bridge clinical medicine, academic excellence, and impactful scientific contributions to global health.

Author Profile

Orcid

Education

Syed Aasim Syed Nasir began his educational journey at Our Own English High School, Sharjah, UAE (2007–2019), where he developed a strong academic foundation. He then pursued his higher education at Velammal Vidhyashram School, Chennai, excelling in the sciences and preparing for a career in medicine. In 2021, he enrolled at Tbilisi State Medical University – School of Medicine, Georgia, where he is currently a Doctor of Medicine candidate. His education extends beyond formal coursework, as he participates in research training, medical writing, and scientific presentations at both national and international levels. His certifications in PALS, First Aid, CPR, ACLS, and BLS (in progress) add clinical preparedness to his academic excellence. Actively engaged in self-directed learning, he complements his curriculum with research in cardiology, oncology, and obstetrics, bridging classroom knowledge with real-world medical applications, shaping him into a future physician-scientist of global relevance.

Experience

Syed Aasim’s experience spans clinical exposure, research collaborations, leadership, and volunteerism. He completed observerships at Zulekha Hospital, Dubai, gaining insights into multidisciplinary patient care, and undertook a Psychnovation Neuroscience Internship, Nigeria, enhancing his research and clinical interpretation skills. He has served as a part-time researcher with the International Journal of Clinical Research (IJCR) and contributed to cardiology projects within IJCR Research Working Group. His leadership roles include General Secretary of ClinNova International, PR Team Member of IJCR Conference, Judiciary Council Member at GIMSOC, and University Head Representative. He also actively participated in Project IMG (USA) as a Unity Agent, furthering international student collaboration. His experiences combine academic rigor with hands-on exposure to clinical medicine, surgical case analysis, systematic reviews, and patient-centered research. These engagements reflect his commitment to developing as a medical leader, researcher, and clinician with both local and international impact.

Awards and Honors

Though early in his career, Syed Aasim has already earned recognition in multiple academic and professional avenues. His posters and case reports have been accepted and presented at high-impact platforms such as the Royal Society of London (2025) and the European Hip Society Congress, Thessaloniki, Greece (2025). His research on oncology, orthopedics, cardiology, and obstetrics has been acknowledged in international medical conferences, highlighting his ability to address complex diagnostic and therapeutic challenges. His selection as Georgia Ambassador for IJCR (2024–2025) underscores his leadership in research dissemination. Additionally, his active participation in medical student societies such as GIMSOC, SSSG, IASSS, and ClinNova International showcases his growing influence in academic medicine. These honors reflect both academic excellence and his proactive approach to advancing collaborative medical research. His consistent recognition in prestigious forums demonstrates his trajectory toward becoming a globally respected physician-researcher in medicine.

Research Focus

Syed Aasim’s research focuses on advancing clinical medicine through a multidisciplinary approach. His work spans oncology, cardiology, orthopedics, neurology, infectious diseases, and obstetrics/gynecology, reflecting his commitment to solving pressing healthcare challenges. He has investigated glioblastoma surgical outcomes, pharmacological mechanisms of UV-induced skin mutations, rheumatological impacts on cardiovascular health, and surgical complexities in gynecological disorders. His systematic reviews and meta-analyses address critical gaps in evidence-based medicine, such as hip arthroplasty, meniscal tear management, and cardiotoxicity biomarkers in cancer patients. He also explores therapeutics in infectious disease management, contributing reviews on measles outbreaks and innovative treatment strategies. His interest in women’s health and perinatal care is reflected in ongoing studies on melatonin supplementation in pregnancy and heart failure outcomes in women versus men. With a balance between clinical case reports, systematic reviews, and mechanistic research, his focus lies in generating translational insights that directly impact patient care and public health.

Publications

  1. A Diagnostic Chameleon: Genital Tuberculosis Mimicking Ovarian Malignancy – Case Report.

  2. Uterine Didelphys with OHVIRA Syndrome: Diagnostic and Surgical Challenges.

  3. Navigating the Pharmacological Landscape of UV-Induced Mutations in Skin Carcinogenesis.

  4. Comprehensive Review of Measles: Outbreak Trends, Clinical Manifestations, and Therapies.

  5. Glioblastoma Surgery: Comparative Study of Resection Degree and Survival Results.

  6. Rheumatoid Arthritis and Cardiovascular Mortality Trends in Postmenopausal Women.

  7. Glioblastoma Multiforme Surgery: Comparative Survival Investigation – IJCR 2024.

  8. Arthroscopic Partial Meniscectomy vs Exercise Therapy for Meniscal Tear: Systematic Review.

  9. Short Stem vs Standard Stem Total Hip Arthroplasty: A Systematic Review.

  10. Melatonin Supplementation in Pregnant Women: Neonatal Brain Maturation Study (In Progress).

  11. Impact of SGLT2 Inhibitors on HFpEF Outcomes: Gender-Based Analysis (In Progress).

  12. Rapid-Onset Obesity with Hypothalamic Dysfunction: Comprehensive Review (In Review).

  13. Infective Endocarditis Post-TAVR vs SAVR: A Comparative Study (In Review).

  14. NT-ProBNP/BNP vs Troponins in Chemotherapy-Induced Cardiotoxicity Detection (In Progress).

  15. Impact of Hydrotherapy in Sports Medicine (In Progress).

Conclusion

Syed Aasim Syed Nasir embodies the qualities of a future physician-scientist: rigorous academic training, international exposure, leadership in medical organizations, and impactful research contributions across diverse medical domains. His growing portfolio of publications, presentations, and leadership roles underscores his ability to bridge clinical practice and academic medicine. With a strong commitment to innovation and patient-centered research, he is positioned to make significant contributions to medicine and global healthcare. His trajectory reflects not only individual excellence but also the potential to influence future medical research and practice on a global scale.

 

Do Young Kim | Medicine | Best Researcher Award

Published on by Academic Excellence

Prof. Do Young Kim | Medicine | Best Researcher Award

Prof. Do Young Kim, Yonsei University College of Medicine South Korea

Do Young Kim is a Professor of Internal Medicine at Yonsei University College of Medicine and a hepatologist at Severance Hospital in Seoul, Korea. Having been part of the faculty since 2007, Dr. Kim is widely recognized for his contributions to hepatology, particularly in hepatocellular carcinoma (HCC). He earned his medical degree from Yonsei University in 1996 and completed his training at Severance Hospital. Dr. Kim’s research experience includes a position as a research associate at Fred Hutchinson Cancer Research Center from 2011 to 2012, where he focused on proteomics and microRNA in HCC.

Professional Profile 

Scopus 

Orcid

Google Scholar

Summary of Suitability for the “Research for Best Researcher Award”

Professor Do Young Kim, a prominent figure in hepatology and internal medicine, has made significant contributions to the field of hepatocellular carcinoma (HCC) and hepatitis C research. As a professor at Yonsei University College of Medicine and a hepatologist at Severance Hospital, he has established himself as a leading expert in his field since 2007. His academic background, including his degree from Yonsei University and specialized training at Severance Hospital, laid a solid foundation for his remarkable career.

His research focus on proteomics and microRNA in HCC, particularly during his tenure at the Fred Hutchinson Cancer Research Center, has led to innovative insights into the mechanisms underlying liver cancer and hepatitis C. This focus has translated into a series of impactful publications, where he has served as the corresponding author in studies that explore new treatment paradigms and diagnostic advancements for HCC. His work on the efficacy and safety of various treatments, including sorafenib and lenvatinib, has become essential reading for clinicians and researchers alike.

🎓 Education 

Dr. Do Young Kim obtained his medical degree from Yonsei University in Seoul, Korea, in 1996. After completing his studies, he underwent medical training at Severance Hospital, where he continued his professional development until 2001. In 2011, Dr. Kim broadened his academic horizons by becoming a research associate at Fred Hutchinson Cancer Research Center, where he focused on proteomics and microRNA in hepatocellular carcinoma (HCC). This international research experience allowed him to deepen his expertise in the molecular aspects of liver cancer. Dr. Kim’s ongoing contributions to medical education and his research have been deeply influenced by his foundational education and global training experiences.

💼 Professional Experience 

Dr. Do Young Kim is currently serving as a Professor of Internal Medicine at Yonsei University College of Medicine and a hepatologist at Severance Hospital in Seoul, Korea. Since joining Severance Hospital in 2007, he has become an integral part of the team, specializing in hepatology and liver diseases. His research has advanced understanding in areas such as hepatocellular carcinoma (HCC) and hepatitis C. In 2011-2012, Dr. Kim expanded his professional expertise by working as a research associate at the Fred Hutchinson Cancer Research Center in Seattle, USA. There, he conducted cutting-edge research in proteomics and microRNA in relation to HCC, which added a new dimension to his medical and scientific career. His ongoing clinical and research contributions have made him a leader in the field of hepatology.

🏅 Awards and Recognition

Dr. Do Young Kim has received significant recognition in the field of hepatology, with several prestigious awards throughout his career. His research on hepatocellular carcinoma (HCC) and hepatitis C has earned him acknowledgment both nationally and internationally. He is particularly recognized for his contributions to clinical practices surrounding HCC and his extensive publication record in highly respected medical journals. His role as a corresponding author in key studies, such as those published in Hepatology and J Gastroenterol Hepatol, highlights his leadership in advancing knowledge about liver disease. Dr. Kim’s research and clinical expertise have earned him the trust and respect of colleagues in the medical community, solidifying his position as a leading expert in the field of internal medicine and hepatology.

🌍 Research Skills On Medicine

Dr. Do Young Kim’s research skills are highly regarded, particularly in the fields of hepatocellular carcinoma (HCC) and hepatitis C. He specializes in proteomics and microRNA, utilizing these molecular techniques to gain deeper insights into the pathophysiology of liver diseases. His time at the Fred Hutchinson Cancer Research Center honed his skills in advanced research methodologies, which he continues to apply in his work at Severance Hospital and Yonsei University College of Medicine. Dr. Kim’s research is both experimental and clinical, bridging the gap between laboratory findings and real-world medical applications. He is skilled in conducting large-scale studies, analyzing complex data, and collaborating with multidisciplinary teams to advance scientific understanding. His research has led to significant clinical improvements in the management of liver diseases, particularly in HCC treatment and early detection.

📖 Publication Top Notes

  • Letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
    • Authors: Chon, Y.E., Kim, D.Y., Chon, H.J., Kim, D.Y.
    • Citation: Clinical and Molecular Hepatology, 2025, 31(1), pp. e98–e100
  • The Possible Impact of Zinc-Enriched Multivitamins on Treatment-Naïve Recurrent Aphthous Stomatitis Patients
    • Authors: Seo, H.R., Chung, K.B., Kim, D.-Y.
    • Citation: Journal of Clinical Medicine, 2025, 14(1), 260
  • Survey on Alopecia Areata Patients’ Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study
    • Authors: Kim, J.E., Lee, S., Kang, H., Lee, Y.W., Kim, M.-B.
    • Citation: Annals of Dermatology, 2024, 36(6), pp. 376–383
  • Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study
    • Authors: Kim, K.-P., Kim, K.M., Ryoo, B.-Y., Kim, J.-A., Kim, K.-H.
    • Citation: Liver Cancer, 2024, 13(6), pp. 610–628
  • Detection of NUDT15 R139C Variants and Azathioprine Utilization in Patients with Dermatologic Conditions
    • Authors: Chung, K.B., Sung, H., Kim, D.-Y.
    • Citation: International Journal of Dermatology, 2024, 63(3), pp. e75–e77
  • Quantitative Analysis of Hair Luster in a Novel Ultraviolet-Irradiated Mouse Model
    • Authors: Chung, K.B., Lee, Y.I., Kim, Y.J., Kim, D.-Y., Lee, J.H.
    • Citation: International Journal of Molecular Sciences, 2024, 25(3), 1885
    • Citations: 1
  • Heterogeneity in Keloid Scars: Influence of Mechanical Stretching on Keloids Arising from Different Anatomical Sites
    • Authors: Lee, Y.I., Yang, Y., Ham, S., Kim, D.-Y., Lee, J.H.
    • Citation: Journal of Investigative Dermatology, 2024
  • The Efficacy of Treatment for Hepatocellular Carcinoma in Elderly Patients
    • Authors: Lee, H.A., Lee, S., Lee, H.L., Rhim, H., Kim, D.Y.
    • Citation: Journal of Liver Cancer, 2023, 23(2), pp. 362–376
    • Citations: 2
  • Predictive Biomarkers of Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Treatment
    • Authors: Chon, Y.E., Cheon, J., Kim, H., Chon, H.J., Kim, B.K.
    • Citation: Cancer Medicine, 2023, 12(3), pp. 2731–2738
    • Citations: 26
  • Activated TAZ Induces Liver Cancer in Collaboration with EGFR/HER2 Signaling Pathways
    • Authors: Moon, H., Park, H., Chae, M.J., Kim, D.Y., Ro, S.W.
    • Citation: BMC Cancer, 2022, 22(1), 423
    • Citations: 11